Go Pro
NASDAQ:RXST

RxSight Q2 2026 Earnings Report

RxSight logo
$5.06 +0.11 (+2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$5.07 +0.01 (+0.10%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RxSight EPS Results

Actual EPS
N/A
Consensus EPS
-$0.21
Beat/Miss
N/A
One Year Ago EPS
N/A

RxSight Revenue Results

Actual Revenue
N/A
Expected Revenue
$32.47 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

RxSight Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

RxSight Earnings Headlines

Piper Sandler Keeps Their Hold Rating on RxSight (RXST)
Wells Fargo Sticks to Its Hold Rating for RxSight (RXST)
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
See More RxSight Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RxSight? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RxSight and other key companies, straight to your email.

About RxSight

RxSight (NASDAQ:RXST) is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. The company obtained CE marking in Europe for its LAL technology and later secured U.S. Food and Drug Administration approval for its second‐generation device in October 2020. Since then, RxSight has partnered with leading ophthalmology centers to integrate the LAL system into clinical practice, building a network of implantation sites throughout North America and preparing for broader global expansion under existing regulatory frameworks.

In addition to its core LAL offering, RxSight continues to invest in research and development aimed at enhancing its lens portfolio and refining adjustment protocols. The company collaborates with ophthalmic surgeons and research institutions to advance surgical workflows and patient education initiatives. Under the leadership of President and Chief Executive Officer Steve McKnight, RxSight is committed to driving innovation in presbyopia correction and setting new standards for patient-centric eye care solutions.

View RxSight Profile